Cover image of the article: Effects of drug therapy of visceral leishmaniasis on serum level of IFN-γ, IL-10 and IL-12 in visceral leishmaniasis patients

Image Credit:Zahedan J Res Med Sci

Effects of drug therapy of visceral leishmaniasis on serum level of IFN-γ, IL-10 and IL-12 in visceral leishmaniasis patients

Authors

abolfazl khoshdel1,*, abdolvahab alborzi2, manoochehr Rasouli2, elham Taheri3
1Dept of Pediatrics, Shahrekord University of Medical Sciences and Health Services, Shahrekord. Iran
2Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences and Health Services, Shiraz, Iran
3General Physician, Shaharekord University of Medical Sciences and Health Services, Shahrekord, Iran.
*Corresponding Author: Dept of Pediatrics, Shahrekord University of Medical Sciences and Health Services, Shahrekord. Iran Email: nikakhosh@gmail.com

Zahedan Journal of Research in Medical Sciences:Vol. 10, issue 1; e92278
Published online:Mar 03, 2008
Article type:Research Article
Received:Feb 11, 2008
Accepted:Jun 24, 2008
How to Cite:khoshdel A, alborzi A, Rasouli M, Taheri E. Effects of drug therapy of visceral leishmaniasis on serum level of IFN-γ, IL-10 and IL-12 in visceral leishmaniasis patients. Zahedan J Res Med Sci. 2008;10(1):e92278. doi:

Abstract

Background: Leishmaniosis has remained a serious public health problem in several parts of the developing world. Effective prophylacyic measurements are hampered by imprecise understanding of different aspects of the disease, including its immunoregulation. A better understanding of immunoregulation in human visceral leishmaniosis may be useful both for designing and evaluating immunoprophylaxis. Materials and Methods: This before-after interventional study investigated immunoregulatory mechanisms among 32 patients with visceral leishmaniasis in Shiraz (Iran) in 2007. The plasma cytokine (IFN-gamma, IL-10 and IL-12) levels of participants were measured before, during active disease and at different periods up to 2 months after treatment. Results: Elevated plasma levels of IFN-γ, IL-10 and IL-12 which were observed during active disease, decreased significantly after treatment. The main candidate for blunting IFN- γ activity seems to be IL-10, since the level of this cytokine which highly elevated in plasma decreased sharply after treatment (Before treatment 88.3±77.5, after treatment 25±18.3, 2months after treatment 517±1.9). difference between samples was significant (P<0/05) Discussion: Results suggest that IFN- γ and IL-10 are the molecules most likely involved in determining fate of the disease. After treatment, there is a long delay before the immune profile returns to its normal level which precludes using plasma cytokine levels as criteria for certain cure diagnosis of the disease.

Highlights

Fulltext

The body is available in pdf file.

References

  • 1.
    The references are available in pdf file.

Copyright

© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

7
Jun
2016
Visceral Leishmaniasis: An Update and Literature Review

Visceral Leishmaniasis: An Update and Literature Review

Abdollah Karimi,
Abdolvahab Alborzi,
Ali Amanati

Karimi A, Alborzi A, Amanati A. Visceral Leishmaniasis: An Update and Literature Review. Arch Pediatr Infect Dis. 2016;4(3):e31612. doi: https://doi.org/10.5812/pedinfect.31612

31
Jul
2011

Clinical Findings and Initial Treatment Response of Patients with Visceral Leishmaniasis Admitted in Ali asghar Children Hospital from 1976 to 2010 in Tehran, Iran

Alireza Nateghian,
Homa Mousavi

Nateghian A, Mousavi H. Clinical Findings and Initial Treatment Response of Patients with Visceral Leishmaniasis Admitted in Ali asghar Children Hospital from 1976 to 2010 in Tehran, Iran. Arch Clin Infect Dis. 2011;6(3):. doi:

31
Oct
2014
Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis

Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis

Abdolali Malmasi,
Bijan Ziaie Ardestani,
Mehdi Mohebali,
Behnaz Akhoundi,
Shadi Ziaie,
Majid Masoudifard
,et al.

Malmasi A, Ziaie Ardestani B, Mohebali M, Akhoundi B, Ziaie S, et al. Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis. Iran J Pharm Res. 2014;13(4):e125580. doi: https://doi.org/10.22037/ijpr.2014.1573

19
Jul
2011
Characterization of Leishmania isolated from Kala- azar infected patients in Kermanshah using PCR

Characterization of Leishmania isolated from Kala- azar infected patients in Kermanshah using PCR

Mahdi Fakhar,
Masood Keyghobadi,
Reza Akramipour,
Keyghobad Ghadiri,
Mojtaba Limouei

Fakhar M, Keyghobadi M, Akramipour R, Ghadiri K, Limouei M. Characterization of Leishmania isolated from Kala- azar infected patients in Kermanshah using PCR. J Kermanshah Univ Med Sci. 2011;15(2):e79382. doi:

1
Oct
2007
Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.

Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.

M Beheshti

Beheshti M. Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.. Shiraz E-Med J. 2007;8(4):. doi:

More by these authors

abolfazl khoshdelPubMedScholar
abdolvahab alborziPubMedScholar
manoochehr RasouliPubMedScholar
elham TaheriPubMedScholar
Share
Cited by
Metrics